Literature DB >> 12454844

Prevention of colitis by interleukin 10-transduced T lymphocytes in the SCID mice transfer model.

Catherine Van Montfrans1, Maria Sol Rodriguez Pena, Inge Pronk, Fiebo J W Ten Kate, Anje A Te Velde, Sander J H Van Deventer.   

Abstract

BACKGROUND & AIMS: Regulatory CD4(+) cells secreting the anti-inflammatory cytokine interleukin (IL)-10 play a key role in maintaining the immune balance in the intestinal mucosa. In this study we engineered primary CD4(+) cells to express IL-10 and investigated the efficacy of this approach in offering protection against experimental colitis.
METHODS: Spleen-derived CD4(+) cells were transduced by using a retroviral vector to simultaneously express IL-10 and green fluorescent protein (GFP). The therapeutic benefit of CD4(+) cells transduced with IL-10 GFP was studied in experimental colitis, induced by transfer of CD45RB(high) CD4(+) cells to severe combined immunodeficient mice, and in acute trinitrobenzene sulfonic acid (TNBS)-induced colitis.
RESULTS: Transferred engineered GFP fluorescent cells were detected for at least 15 weeks in peripheral blood, spleens, colon, and lymph nodes draining the intestine of recipient SCID mice. IL-10-GFP CD4(+) cells prevented CD45RB(high)-induced transfer colitis effectively, whereas no effect was observed after transfer of nontransduced CD4(+) cells. IL-10-GFP CD45RB(high) CD4(+) cells lost the capacity to induce colitis. By contrast, no therapeutic benefit was observed in TNBS-induced colitis.
CONCLUSIONS: Primary murine CD4(+) cells that were engineered to express IL-10 by retroviral transduction act as regulatory cells in CD45RB(high)-induced transfer colitis. This approach may induce long-term maintenance of mucosal immune homeostasis in Crohn's disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12454844     DOI: 10.1053/gast.2002.37067

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  30 in total

1.  Targeting Therapy in Pediatric Inflammatory Bowel Disease.

Authors:  Marla C. Dubinsky
Journal:  Curr Treat Options Gastroenterol       Date:  2004-10

2.  Reduced ratio of protective versus proinflammatory cytokine responses to commensal bacteria in HLA-B27 transgenic rats.

Authors:  L A Dieleman; F Hoentjen; B-F Qian; D Sprengers; E Tjwa; M F Torres; C D Torrice; R B Sartor; S L Tonkonogy
Journal:  Clin Exp Immunol       Date:  2004-04       Impact factor: 4.330

Review 3.  The role of mucosal T lymphocytes in regulating intestinal inflammation.

Authors:  Holm H Uhlig; Fiona Powrie
Journal:  Springer Semin Immunopathol       Date:  2005-06-15

Review 4.  Recent advances in the understanding of celiac disease: therapeutic implications for the management of pediatric patients.

Authors:  John H Kwon; Richard J Farrell
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 5.  Immunopathogenesis of IBD: insufficient suppressor function in the gut?

Authors:  I L Huibregtse; A U van Lent; S J H van Deventer
Journal:  Gut       Date:  2006-10-17       Impact factor: 23.059

Review 6.  New pathophysiological insights and modern treatment of IBD.

Authors:  Matthias A Engel; Markus F Neurath
Journal:  J Gastroenterol       Date:  2010-03-09       Impact factor: 7.527

7.  Gene and cell therapy based treatment strategies for inflammatory bowel diseases.

Authors:  Sander van der Marel; Anna Majowicz; Sander van Deventer; Harald Petry; Daniel W Hommes; Valerie Ferreira
Journal:  World J Gastrointest Pathophysiol       Date:  2011-12-15

8.  Leukocytapheresis: An "Out-of-Body" Experience in Inflammatory Bowel Disease.

Authors:  Seymour Katz
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-12

9.  Effects of Rheum tanguticum polysaccharide on TNBS -induced colitis and CD4+T cells in rats.

Authors:  Li Liu; Zhi-Peng Wang; Chang-Tai Xu; Bo-Rong Pan; Qi-Bing Mei; Yin Long; Jia-Yun Liu; Si-Yuan Zhou
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

10.  Indium-labelled human gut-derived T cells from healthy subjects with strong in vitro adhesion to MAdCAM-1 show no detectable homing to the gut in vivo.

Authors:  J Kelsen; J Agnholt; L Falborg; J T Nielsen; J L Rømer; H J Hoffmann; J F Dahlerup
Journal:  Clin Exp Immunol       Date:  2004-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.